They identified 1400 patients that received either living donor or deceased donor kidneys. They looked at patient demographics, socioeconomic variables (e.g. insurance status), health status including comorbidities, transplantation variables (e.g. time to transplant, rejection, type of dialysis, graft failure, etc.), and mortality.
Their group found that the AA group had higher wait times for a referral to treatment, higher BMI and higher percentage of reactive antibodies. Furthermore, AAs were less likely to receive a living donor kidney compare to EAs. They also found that graft survival was lower in AA compared to EA, but when graft survival was stratified by donor type, there was no difference in survival in those who received living donor allografts. The AA group had higher chronic rejection and immunosuppression non-compliance rates compared to EAs.
Dr Modlin concludes that AAs have worse graft survival for deceased donor kidneys, but ethnic disparities among AAs and EAs disappear when living donor kidneys are used. Finally, Dr Modlin emphasizes a need to promote immunosuppression compliance and living kidney donations among AAs.
Presented by: Charles S. Modlin, MD
Written by: Egor Parkhomenko, Department of Urology, University of California-Irvine at the 2018 AUA Annual Meeting - May 18 - 21, 2018 – San Francisco, CA USA